Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer

Bibliography

• Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8(4):299-308
   PubMed Web of Science ®Google Scholar
• Leen AM, Tripic T, Rooney CM. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther 2010;10(3):337-51
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319(25):1676-80
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298(5594):850-4
   PubMed Web of Science ®Google Scholar
• Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001;83:117-58
   PubMed Web of Science ®Google Scholar
• Crespo J, Sun H, Welling TH, et al. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 2013;25(2):214-21
   PubMed Web of Science ®Google Scholar
• Barrett DM, Singh N, Porter DL, et al. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014;65:333-47
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, Gornall H, Baldan V, et al. CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev 2014;257(1):91-106
   PubMed Web of Science ®Google Scholar
• Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 2008(181):329-42
   PubMedGoogle Scholar
• Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009;21(2):215-23
   PubMed Web of Science ®Google Scholar
• Friedmann-Morvinski D, Bendavid A, Waks T, et al. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 2005;105(8):3087-93
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5(177):177ra38
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118(18):4817-28
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368(16):1509-18
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116(20):4099-102
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365(8):725-33
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013;122(25):4129-39
   PubMed Web of Science ®Google Scholar
• Porter DL, Kalos M, Frey NV, et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Proceedings of the 55th annual meeting of the American Society of Hematology; 2013
   Google Scholar
• Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18(4):843-51
   PubMed Web of Science ®Google Scholar
• Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013;31(1):71-5
   PubMed Web of Science ®Google Scholar
• Lanitis E, Poussin M, Klattenhoff AW, et al. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused anti-tumor activity with reduced potential for toxicity. Cancer Immunol Res 2013;1(1):43-53
   PubMed Web of Science ®Google Scholar
• Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 2013;5(215):215ra172
   PubMed Web of Science ®Google Scholar
• Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007;25:139-70
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75(3):555-62
   PubMed Web of Science ®Google Scholar
• Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300(19):1068-73
   PubMed Web of Science ®Google Scholar
• Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004;103(3):790-5
   PubMed Web of Science ®Google Scholar
• Dazzi F, Goldman JM. Adoptive immunotherapy following allogeneic bone marrow transplantation. Annu Rev Med 1998;49:329-40
   PubMed Web of Science ®Google Scholar
• Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15(2):433-44
   PubMed Web of Science ®Google Scholar
• Davies JK, Singh H, Huls H, et al. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res 2010;70(10):3915-24
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14(11):1264-70
   PubMed Web of Science ®Google Scholar
• Cruz CR, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013;122(17):2965-73
   PubMed Web of Science ®Google Scholar
• Zakrzewski JL, Suh D, Markley JC, et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol 2008;26(4):453-61
   PubMed Web of Science ®Google Scholar
• Torikai H, Reik A, Liu PQ, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 2012;119(24):5697-705
   PubMed Web of Science ®Google Scholar
• Thedrez A, Sabourin C, Gertner J, et al. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol Rev 2007;215:123-35
   PubMed Web of Science ®Google Scholar
• Constant P, Davodeau F, Peyrat MA, et al. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 1994;264(5156):267-70
   PubMed Web of Science ®Google Scholar
• Gober HJ, Kistowska M, Angman L, et al. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197(2):163-8
   PubMed Web of Science ®Google Scholar
• Braza MS, Klein B. Anti-tumour immunotherapy with Vgamma9Vdelta2 T lymphocytes: from the bench to the bedside. Br J Haematol 2013;160(2):123-32
   PubMed Web of Science ®Google Scholar
• Nakajima J, Murakawa T, Fukami T, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 2010;37(5):1191-7
   PubMed Web of Science ®Google Scholar
• Izumi T, Kondo M, Takahashi T, et al. Ex vivo characterization of gammadelta T-cell repertoire in patients after adoptive transfer of Vgamma9Vdelta2 T cells expressing the interleukin-2 receptor beta-chain and the common gamma-chain. Cytotherapy 2013;15(4):481-91
   PubMed Web of Science ®Google Scholar
• Nicol AJ, Tokuyama H, Mattarollo SR, et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 2011;105(6):778-86
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Tanaka Y, Yagi J, et al. Phase I/II study of adoptive transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother 2011;60(8):1075-84
   PubMed Web of Science ®Google Scholar
• Deniger DC, Switzer K, Mi T, et al. Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther 2013;21(3):638-47
   PubMed Web of Science ®Google Scholar
• Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975;16(2):216-29
   PubMed Web of Science ®Google Scholar
• Benjamin JE, Gill S, Negrin RS. Biology and clinical effects of natural killer cells in allogeneic transplantation. Curr Opin Oncol 2010;22(2):130-7
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010;28(6):955-9
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110(1):433-40
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105(8):3051-7
   PubMed Web of Science ®Google Scholar
• Iliopoulou EG, Kountourakis P, Karamouzis MV, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010;59(12):1781-9
   PubMed Web of Science ®Google Scholar
• Arai S, Meagher R, Swearingen M, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008;10(6):625-32
   PubMed Web of Science ®Google Scholar
• Tonn T, Schwabe D, Klingemann HG, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 2013;15(12):1563-70
   PubMed Web of Science ®Google Scholar
• Esser R, Muller T, Stefes D, et al. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med 2012;16(3):569-81
   PubMed Web of Science ®Google Scholar
• Chu J, Deng Y, Benson DM, et al. CS1-speific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Oberoi P, Wels WS. Arming NK cells with enhanced antitumor activity: CARs and beyond. Oncoimmunology 2013;2(8):e25220
   PubMed Web of Science ®Google Scholar
• Marcus A, Waks T, Eshhar Z. Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood 2011;118(4):975-83
   PubMed Web of Science ®Google Scholar
• Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005;23:127-59
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427(6972):355-60
   PubMed Web of Science ®Google Scholar
• Beilhack A, Schulz S, Baker J, et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood 2008;111(5):2919-28
   PubMed Web of Science ®Google Scholar
• Taylor PA, Ehrhardt MJ, Lees CJ, et al. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). Blood 2007;110(9):3480-8
   PubMed Web of Science ®Google Scholar
• Takada K, Jameson SC. Self-class I MHC molecules support survival of naive CD8 T cells, but depress their functional sensitivity through regulation of CD8 expression levels. J Exp Med 2009;206(10):2253-69
   PubMed Web of Science ®Google Scholar
• Whitmore WF Jr. Natural history and staging of prostate cancer. Urol Clin North Am 1984;11(2):205-20
   PubMed Web of Science ®Google Scholar
• Bondanza A, Valtolina V, Magnani Z, et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 2006;107(5):1828-36
   PubMed Web of Science ®Google Scholar
• Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005;105(11):4247-54
   PubMed Web of Science ®Google Scholar
• Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013;153(4):910-18
   PubMed Web of Science ®Google Scholar